Table 2.

Donor Source and Conditioning Regimens

Study	No. of Patients/Disease at Baseline	Conditioning Regimen	Donor Distribution	Nonrelapse Mortality	OS	Comments
Kroger et al [35]	103/PMF, post-ET MF, post-PV MF	Bu-Flu-ATG	HLA-matched, 82	Overall NRM at 1 y, 16% HLA MRD, 10% 10/10 MUD, 13% MMUD, 38% Completely matched, 12%	OS at 5 yr, 67% HLA-matched, 74% HLA-mismatched, 38% (P = .03)	OS was significantly better in patients <55 yr vs. >55 yr and HLA-matched vs. mismatched donor
Rondelli et al [50]	66/PMF, post-ET MF, post-PV MF	Flu-Mel ATG in unrelated donor HCT	HLA-matched sibling, 30 HLA-mismatched sibling, 2 HLA-matched unrelated, 25 HLA-mismatched unrelated, 9	Median follow-up, 25 mo Sibling donor, 22% Unrelated donor, 59%	Median follow-up, 25 mo Sibling donor, 75% Unrelated donor, 32%	Median for OS not reached in the sibling cohort vs. 6 mo in the unrelated cohort (P < .0001)
Gupta et al [42]	233/PMF	Flu-TBI, 22% Flu-Mel, 28% Bu-Flu, 38% Other RIC, 12%	MRD, 79 MUD, 104 MMUD, 50	Cumulative incidence of NRM at 1 y, 18%; 5 yr, 24% RR for NRM in MUD, 3.92; MMUD, 9.37 (P < .0001)	Adjusted probabilities for survival at 5 yr: MRD, 56% MUD, 48% MMUD, 34% (P = .002)	Donor type was an independent risk factor for NRM and OS

PMF indicates primary myelofibrosis; Bu-Flu, busulfan + fludarabine; ATG, antithymocyte globulin; Flu-Mel, fludarabine + melphalan; Flu-TBI, fludarabine + total body irradiation; NRM, nonrelapse mortality; RR, relative risk.